PMID- 23689226
OWN - NLM
STAT- MEDLINE
DCOM- 20140108
LR  - 20191210
IS  - 1423-0240 (Electronic)
IS  - 0378-584X (Linking)
VI  - 36
IP  - 5
DP  - 2013
TI  - Practical management of everolimus-related toxicities in patients with advanced 
      solid tumors.
PG  - 295-302
LID - 10.1159/000350625 [doi]
AB  - Everolimus is an orally administered inhibitor of the mammalian target of 
      rapamycin (mTOR), an intracellular protein kinase downstream of the 
      phosphatidylinositol 3-kinase/AKT pathway involved in key components of 
      tumorigenesis, including cell growth, proliferation, and angiogenesis. In the 
      advanced cancer setting, based on favorable results from phase III trials, 
      everolimus is indicated for the treatment of advanced renal cell carcinoma, 
      advanced neuroendocrine tumors of pancreatic origin, and advanced hormone 
      receptor-positive, human epidermal growth factor receptor 2-negative breast 
      cancer. Additional oncology indications for everolimus include renal 
      angiomyolipoma with tuberous sclerosis complex and subependymal giant-cell 
      astrocytoma. Although it is generally well tolerated, with most adverse events of 
      mild to moderate severity and manageable, everolimus exhibits a distinct adverse 
      event profile that warrants guidance for proper diagnostic and medical 
      management. This guidance is particularly important given the potential for 
      widespread long-term use of everolimus. This review will focus on the most 
      relevant toxicities associated with mTOR inhibitors and on their management. 
      Practical treatment recommendations are presented for stomatitis, noninfectious 
      pneumonitis, rash, selected metabolic abnormalities, and infections. Provided 
      these events are rapidly identified and treated, the vast majority should resolve 
      with minimal effect on treatment outcomes and patients' quality of life.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Grunwald, Viktor
AU  - Grunwald V
AD  - Klinik fur Hamatologie, Hamostaseologie, Onkologie und Stammzelltransplantation, 
      Medizinische Hochschule Hannover, Germany. gruenwald.viktor@mh-hannover.de
FAU - Weikert, Steffen
AU  - Weikert S
FAU - Pavel, Marianne E
AU  - Pavel ME
FAU - Horsch, Dieter
AU  - Horsch D
FAU - Luftner, Diana
AU  - Luftner D
FAU - Janni, Wolfgang
AU  - Janni W
FAU - Geberth, Matthias
AU  - Geberth M
FAU - Weber, Matthias M
AU  - Weber MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130405
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Everolimus
MH  - Humans
MH  - Infection Control/*methods
MH  - Infections/*chemically induced
MH  - Inflammation/*chemically induced/*prevention & control
MH  - Neoplasms/complications/*drug therapy
MH  - Sirolimus/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2013/05/22 06:00
MHDA- 2014/01/09 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/22 06:00 [entrez]
PHST- 2013/05/22 06:00 [pubmed]
PHST- 2014/01/09 06:00 [medline]
AID - 000350625 [pii]
AID - 10.1159/000350625 [doi]
PST - ppublish
SO  - Onkologie. 2013;36(5):295-302. doi: 10.1159/000350625. Epub 2013 Apr 5.